Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05239728 | A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) | active not recruiting | Phase 3 | 1,800 | Merck Sharp & Dohme LLCINDUSTRY | 32 | May 15, 2026 | clinicaltrials |
| NCT05374512 | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) | active not recruiting | Phase 3 | 644 | AstraZenecaINDUSTRY |
| 23 |
| May 15, 2026 |
| clinicaltrials |
| NCT06691984 | Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) | active not recruiting | Phase 3 | 707 | AmgenINDUSTRY | 22 | May 15, 2026 | clinicaltrials |
| NCT03574571 | A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer | active not recruiting | Phase 3 | 732 | Memorial Sloan Kettering Cancer CenterOTHER | 4 | May 14, 2026 | clinicaltrials |
| NCT04195750 | A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) | active not recruiting | Phase 3 | 755 | Merck Sharp & Dohme LLCINDUSTRY | 23 | May 14, 2026 | clinicaltrials |
| NCT05566795 | DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | active not recruiting | Phase 3 | 418 | Day One Biopharmaceuticals, Inc.INDUSTRY | 30 | May 14, 2026 | clinicaltrials |
| NCT05652894 | A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | active not recruiting | Phase 3 | 190 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT06970847 | 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer(AMPLIFY) | active not recruiting | Phase 3 | 220 | Clarity Pharmaceuticals LtdINDUSTRY | 2 | May 14, 2026 | clinicaltrials |
| NCT07241715 | Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE)(CONVERGENCE) | active not recruiting | Phase 2 / Phase 3 | 300 | National University Hospital, SingaporeOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03017326 | Paediatric Hepatic International Tumour Trial(PHITT) | active not recruiting | Phase 3 | 450 | University of BirminghamOTHER | 14 | May 13, 2026 | clinicaltrials |
| NCT03844048 | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | active not recruiting | Phase 3 | 165 | AbbVieINDUSTRY | 23 | May 13, 2026 | clinicaltrials |
| NCT04550260 | Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC(KUNLUN) | active not recruiting | Phase 3 | 640 | AstraZenecaINDUSTRY | 16 | May 13, 2026 | clinicaltrials |
| NCT04055493 | Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC(ADAPTcycle) | active not recruiting | Phase 3 | 1,684 | Women's Cancer Study Group GmbHOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05243550 | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer(ENVISION) | active not recruiting | Phase 3 | 240 | UroGen Pharma Ltd.INDUSTRY | 10 | May 11, 2026 | clinicaltrials |
| NCT05780372 | Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 474 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06230224 | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma(OLYMPIA-4) | active not recruiting | Phase 3 | 216 | Regeneron PharmaceuticalsINDUSTRY | 14 | May 11, 2026 | clinicaltrials |
| NCT01368588 | Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer | active not recruiting | Phase 3 | 2,590 | Radiation Therapy Oncology GroupNETWORK | 6 | May 8, 2026 | clinicaltrials |
| NCT05294172 | KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 295 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05347134 | SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | active not recruiting | Phase 3 | 254 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05870319 | A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients | active not recruiting | Phase 3 | 376 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06295731 | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC(HexAgon-HN) | active not recruiting | Phase 2 / Phase 3 | 410 | Inhibrx Biosciences, IncINDUSTRY | 13 | May 8, 2026 | clinicaltrials |
| NCT06448312 | A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 406 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06968585 | A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy(A166) | active not recruiting | Phase 3 | 365 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT01398085 | IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients(IoN) | active not recruiting | Phase 2 / Phase 3 | 504 | University College, LondonOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04116047 | CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)(CompARE) | active not recruiting | Phase 3 | 785 | University of BirminghamOTHER | 2 | May 7, 2026 | clinicaltrials |
| NCT04175210 | Prospective Randomized Study of Accelerated Radiation Therapy (PRART)(PRART) | active not recruiting | Phase 3 | 397 | Weill Medical College of Cornell UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05089734 | Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)(EVOKE-01) | active not recruiting | Phase 3 | 603 | Gilead SciencesINDUSTRY | 20 | May 7, 2026 | clinicaltrials |
| NCT02446444 | Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer(ENZARAD) | active not recruiting | Phase 3 | 802 | University of SydneyOTHER | 9 | May 6, 2026 | clinicaltrials |
| NCT02488967 | Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | active not recruiting | Phase 3 | 782 | NRG OncologyOTHER | 2 | May 6, 2026 | clinicaltrials |
| NCT02918084 | CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer(GIM10-CONSENT) | active not recruiting | Phase 3 | 1,000 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04136353 | Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate(DASL-HiCaP) | active not recruiting | Phase 3 | 1,100 | University of SydneyOTHER | 6 | May 6, 2026 | clinicaltrials |
| NCT01202851 | Relaxation for Women With Breast Cancer Undergoing Radiotherapy | active not recruiting | Phase 3 | 681 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04217278 | A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT(COSI) | active not recruiting | Phase 2 / Phase 3 | 333 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04564157 | New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy(NADIM-ADJUVANT) | active not recruiting | Phase 3 | 210 | Fundación GECPOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04586231 | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) | active not recruiting | Phase 3 | 747 | Merck Sharp & Dohme LLCINDUSTRY | 25 | May 5, 2026 | clinicaltrials |
| NCT05173987 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | active not recruiting | Phase 3 | 280 | Merck Sharp & Dohme LLCINDUSTRY | 27 | May 5, 2026 | clinicaltrials |
| NCT05429268 | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)(firmMIND) | active not recruiting | Phase 3 | 82 | Incyte CorporationINDUSTRY | 14 | May 5, 2026 | clinicaltrials |
| NCT07226752 | A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China | active not recruiting | Phase 3 | 72 | GenmabINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT03319667 | A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant(IMROZ) | active not recruiting | Phase 3 | 475 | SanofiINDUSTRY | 21 | May 4, 2026 | clinicaltrials |
| NCT03757949 | Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery | active not recruiting | Phase 3 | 203 | SWOG Cancer Research NetworkNETWORK | 1 | May 4, 2026 | clinicaltrials |
| NCT03772834 | Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer | active not recruiting | Phase 2 / Phase 3 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05804045 | Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) | active not recruiting | Phase 3 | 94 | Abbisko Therapeutics Co, LtdINDUSTRY | 7 | May 4, 2026 | clinicaltrials |
| NCT01558921 | Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial(RAPIDO) | active not recruiting | Phase 3 | 920 | University Medical Center GroningenOTHER | 7 | May 1, 2026 | clinicaltrials |
| NCT04241185 | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | active not recruiting | Phase 3 | 520 | Merck Sharp & Dohme LLCINDUSTRY | 25 | May 1, 2026 | clinicaltrials |
| NCT00433420 | Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer | active not recruiting | Phase 3 | 2,000 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyOTHER | 0 | Apr 30, 2026 | clinicaltrials |
| NCT03206671 | Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents(B-NHL 2013) | active not recruiting | Phase 3 | 650 | University Hospital MuensterOTHER | 8 | Apr 30, 2026 | clinicaltrials |
| NCT06117774 | Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)(DeLLphi-306) | active not recruiting | Phase 3 | 404 | AmgenINDUSTRY | 27 | Apr 29, 2026 | clinicaltrials |
| NCT01905046 | Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer | active not recruiting | Phase 3 | 86 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT04384484 | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(LOTIS 5) | active not recruiting | Phase 3 | 440 | ADC Therapeutics S.A.INDUSTRY | 21 | Apr 28, 2026 | clinicaltrials |
| NCT05705401 | Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer(HERO) | active not recruiting | Phase 3 | 1,300 | NRG OncologyOTHER | 2 | Apr 27, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2026source: clinicaltrials